Skip to main content
Premium Trial:

Request an Annual Quote

IDBS to Acquire InforSense

NEW YORK (GenomeWeb News) - ID Business Solutions has inked an agreement to acquire InforSense for an undisclosed sum, IDBS announced today.

The all-cash deal is expected to be completed in July.

IDBS said that the addition of InforSense's product portfolio will expand the firm's large-scale data integration efforts and broaden its life sciences portfolio into the growth areas of biomarker development and personalized medicine. Guildford, UK-based IDBS said that InforSense has developed "state of the art applications to integrate genomics, biomarker and clinical data, that provide a unique offering to researchers in the developing areas of translational and personalised medicine."

"This is a major enabling step towards becoming the number one informatics partner of R&D worldwide," Neil Kipling, CEO and founder of IDBS, said in a statement. "An additional facet of this acquisition is the opportunity to cement a strategic informatics research relationship with Imperial College. The combination of our rigorous software development and powerful new research capabilities creates a groundbreaking new organisation."

Following the deal, InforSense Founder Yi Ke Guo will become chief innovation officer at IDBS.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.